RecruitingPhase 2NCT05661903

From Nerve to Brain: Toward a Mechanistic Understanding of Spinal Cord Stimulation in Human Subjects


Sponsor

Massachusetts General Hospital

Enrollment

180 participants

Start Date

Jun 8, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This is a multicenter prospective study of patients who currently have stably implanted spinal cord simulators. Patients will be randomly assigned to turn on or off their spinal cord stimulators for two week intervals up to six weeks after enrollment, and on the final day of study participation, for one hour intervals, in a multi-crossover design. In a subset of patients we will also perform combined positron emission tomography/magnetic resonance imaging at baseline, week 2 and week 4.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria5

  • Aged 18 to 80
  • Capable of providing informed consent and following trial procedures, including capacity to complete self-reported measures of pain, function, and other outcomes
  • Stably implanted spinal cord or dorsal root ganglion stimulator
  • Device is to treat back/radicular lower extremity pain or neck/arm pain
  • Device with a paresthesia-free setting

Exclusion Criteria12

  • Patients who are not on a stable dose of opioids or are on a stable dose greater than 100 MME/day per day within the two months prior to enrollment, or those who are unwilling to maintain a stable dose of opioids throughout the duration of the study
  • The investigator concludes that the participant is unable to differentiate back or neck/arm pain from other pains
  • Systemic or psychiatric illness that in the opinion of the site investigator would interfere with the individual's ability to participate in the trial
  • Other factor that in the opinion of the site investigator would interfere with the individual's ability to participate in the trial or tolerate the study procedures
  • Dropout Criteria for Optional Imaging
  • Stimulation device is not 3 Tesla magnetic resonance imaging compliant
  • Contraindications to magnetic resonance imaging and/or positron emission tomography scanning (including presence of a cardiac pacemaker or pacemaker wires, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia)
  • Pregnant or breastfeeding
  • Participants with a low affinity binder phenotype based off testing for the Ala147Thr polymorphism.
  • Current or recent use of benzodiazepines (except for alprazolam, clonazepam, and lorazepam). Recent use will be defined based off the benzodiazepines half-life, such that patients who stopped taking the medication at least five half-lives ago will be considered eligible for scanning.
  • Subjects who have exceeded (or would exceed if they were to participate) the yearly amount of allowable radiation, as defined by the Radiation Safety Committee
  • In the opinion of the investigators, unable to safely participate in this study and/or provide reliable data (e.g., unlikely to remain still during the imaging procedures).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSpinal Cord Stimulator Set to Minimal/No Stimulation Setting

Patients in this intervention group will have their spinal cord stimulator turned off or to the minimal settings possible.

OTHERUsual Care

Patients in this intervention group will have their spinal cord stimulator turned on to their usual stimulation settings.

DRUGPositron Emission Tomography / Magnetic Resonance Imaging

Patients with imaging compatible devices will undergo positron emission tomography/magnetic resonance imaging at three time points during the study. This imaging involves administration of the \[11C\]PBR28 radioligand, which is an investigational drug. Only a subset of patients who have 3 Tesla magnetic resonance imaging compatible stimulators will undergo this imaging.


Locations(3)

Massachusetts General Hospital

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05661903


Related Trials